Loading…
← CockpitCompetitor Analysis › OMDA Omada Health, Inc.Open in the cockpit ↗

Omada Health, Inc.OMDACompetitor analysis, valuation and peers

United States · USD·Information Technology›Internet Software/Services

Provides digital chronic-disease management programs (diabetes, hypertension, musculoskeletal) via app and health coaching for employers and health plans.

Momentum laggard 12
Mkt cap
$817M
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$21.4M
20-day average traded
Fwd P/E
28.3×
forward earnings
ROIC−WACC
+2.4 pp
WACC 15.7%
Hurdle
+1 pp
Req g minus delivered
Next earnings
113 days
11 Mar 2027
Close · USD$13.17
1D-6.5%
1W-13.6%
1M-31.9%
3M-44.5%
6M-20.3%
YTD-16.5%
1Y-32.3%
ATR %8.1%
Beta1.16
52w lowhigh48.2% off high

What Omada Health does

Provides digital chronic-disease management programs (diabetes, hypertension, musculoskeletal) via app and health coaching for employers and health plans.

Is paid by employers and health plans rather than by the patient, mainly as a fee per enrolled member, with part of the fee tied to health results. It added support for patients taking GLP-1 weight-loss drugs, and went public in 2025.

Products and services

  • Diabetes prevention/management program
  • Hypertension management
  • Musculoskeletal (MSK) program

Customers

  • Employers
  • Health plans/insurers

Where it sits in the supply chain

  • Digital health
  • Virtual chronic care management…
  • Employers and health plans (B2B2C)

What could go right

  • Employer/payer digital health adoption
  • Value-based care contract growth

What could go wrong

  • Long enterprise sales cycles
  • Competition from well-funded digital health peers

Moat: narrow (data, customer qualification, installed base). Clinical outcomes data and embedded employer/health-plan contracts create switching costs versus newer entrants.

Headquarters: San Francisco, California, United States · Founded: 2011 · Employees: 916

Named competitors

Omada Health at a glance

Size Omada Health (OMDA) is a United States Information Technology company (Internet Software/Services) with a market value of $817M, the 2356th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.17 on 18 Nov 2026.

Performance Over six months the shares fell 20.3%, against -2.5% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 43.3% over the last twelve months (peer median +10.4%); the operating margin is 2.1% (peer median 9.2%).

Valuation It trades at 28.3× forward earnings against a peer median of 14.3× (6th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is +43%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.4 points above its cost of capital (15.7% WACC).

Short interest Short interest is 14.8% of the free float (30 Oct 2026).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026Peer median 96OMDA 80
Six months, rebased to 100: Omada Health against the median of its 20 peers (local-currency closes).

Omada Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$333M$260M$170M$123M$89.2M
Revenue growth—+53%+38%+38%—
Gross profit$235M$170M$102M$69.3M$42.0M
EBITDA$13.1M-$6.48M-$38.9M-$61.5M-$68.0M
Net income$14.0M-$12.8M-$47.1M-$67.5M-$72.5M
Free cash flow$28.2M$16.9M-$34.8M-$50.2M-$68.4M
Capital expenditure$6.20M$5.83M$3.86M$2.92M$2.72M
Total debt$0$0$30.2M$30.6M$30.8M

Quarterly statements and history in the cockpit →

Omada Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-40%-20%0%+20%2273IXIGOTMVNXDRYALA7685PXEDLZFUBOSIFYATGPUBMIQHEPSCARSEVERBCGSDRMOON4819OMDA6-month return →1-month return →
Up and to the right = strong over both horizons. Omada Health is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×100×200×300×2273IXIGOTMVNXDRYALA7685LZATGPUBMEVERSDR4819OMDARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Omada Health is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%2273IXIGOTMVNXDR7685LZATGPUBMCARSEVERBCGSDRMOONOMDAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Omada Health is the large dot.

Omada Health competitors and peer comparison

Head to head with its named competitors (OMDA vs TDOC vs HNGE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Omada Health OMDA$817M-20%+43%2%28.3×44.4%
Teladoc Health TDOC$1.47B+24%-2%-5%n/a-6.4%
Hinge Health HNGE$9.31B+109%+50%19%39.2×34.3%

How Omada Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Omada Health against its 20 peers (data as of 18 Nov 2026)
MeasureOMDAPeer medianRank in peer set
1-month return-31.9%-2.9%3rd lowest of 21
6-month return-20.3%-2.5%8th lowest of 21
Distance from 52-week high-48.2%-36.3%6th lowest of 21
Revenue growth (TTM)+43.3%+10.4%3rd highest of 21
Operating margin2.1%9.2%8th lowest of 21
Forward P/E28.3×14.3×6th most expensive of 17
Growth the price implies (Req g, 7 yrs)44.4%3.5%2nd most demanding of 14
Growth delivered (Del g)+42.9%+15.9%3rd highest of 14
Hurdle (Req g minus delivered)+1.5 pp-11.0 pp3rd most demanding of 14
ROIC minus cost of capital+2.4 pp+0.1 pp9th highest of 19
Net debt / EBITDA-18.6×-0.4×2nd least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Omada Health OMDAUnited States$817M-20%+43%2%28.3×44.4%+42.9%
Gushengtang 2273.HKHong Kong$828M+2%+12%13%12.7×1.8%+27.6%
Le Travenues Technology IXIGO.NSIndia$834M+9%+16%6%50.5×40.0%+55.4%
TeamViewer TMV.DEGermany$786M-20%+2%34%4.7×-12.0%+10.4%
Nextdoor NXDRUnited States$774M-3%+12%-11%85.0×4.8%+15.9%
Yalla Group Ltd. Sponsored ADR YALAUnited States$872M-2%-4%28%7.9×n/an/a
BuySell Technologies 7685.TJapan$881M-34%+52%11%14.3×-3.6%+46.8%
Phoenix Education Partners PXEDUnited States$754M-28%+1%17%5.2×n/an/a
LegalZoom.com LZUnited States$748M-30%+10%6%6.5×-0.3%+9.9%
FuboTV FUBOUnited States$735M-27%+276%-2%n/an/an/a
Sify Technologies Limited Sponsored ADR SIFYUnited States$918M-23%+11%8%n/an/an/a
Auction Technology ATG.LUnited Kingdom$720M+12%+22%11%15.0×21.7%+32.6%
PubMatic PUBMUnited States$947M+92%+4%2%105.3×46.0%+13.7%
iQIYI, Inc. Sponsored ADR IQUnited States$682M-46%-2%-1%n/an/an/a
D-MARKET Elektronik Hizmetler ve Ticaret AS Sponsored ADR HEPSUnited States$982M0%+15%-3%n/an/an/a
Cars.com CARSUnited States$677M+33%+1%13%5.7×3.0%+5.7%
EverQuote EVERUnited States$1.00B+51%+24%11%14.3×-7.1%+14.8%
Baltic Classifieds BCG.LUnited Kingdom$1.05B-99%+7%68%0.2×14.5%+15.9%
SiteMinder SDR.AXAustralia$626M+16%+19%-2%92.3×21.3%+21.4%
Moonpig MOON.LUnited Kingdom$1.08B+33%+7%21%14.9×3.5%+0.3%
Digital Garage 4819.TJapan$615M-10%+2%-7%313.1×n/an/a

Questions

Who are Omada Health's main competitors?
Named competitors: Teladoc (Livongo) (TDOC), Virta Health (private or unlisted), Vida Health (private or unlisted), Hinge Health (HNGE). The cockpit's measured peer set (industry) also includes Gushengtang (2273.HK), Le Travenues Technology (IXIGO.NS), TeamViewer (TMV.DE), Nextdoor (NXDR), Yalla Group Ltd. Sponsored ADR (YALA), BuySell Technologies (7685.T).
Is Omada Health expensive compared with its peers?
On forward p/e it trades at 28.3× against a peer median of 14.3×, 6th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is +43%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Omada Health stock performed?
Over six months to 18 Nov 2026 the shares returned -20.3% against -2.5% for the median peer; over one year -32.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.